- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.01. | Acuitas takes majority stake in Montreal-based RNA construct manufacturer | ||
| 08.01. | Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub | ||
| 07.01. | Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication | ||
| 07.01. | FDA untitled letter skewers Esperion's claims about cholesterol med Nexlizet in TV ad | ||
| 07.01. | Daiichi taps Genesis to handle commercialization of leukemia med Vanflyta in 13 European countries | ||
| 07.01. | Viking enlists commercial chief to battle obesity giants, while Aspen names CCO to prep for Parkinson's launch | ||
| 07.01. | Lilly's prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate | ||
| 06.01. | Jazz touts Ziihera as the new HER2 agent of choice in stomach cancer | ||
| 06.01. | M+C Saatchi taps former Pfizer CMO Freda Lewis-Hall as 1st medical advisor | ||
| 06.01. | J&J's Tremfya outstrips AbbVie's Skyrizi again, closing out 2025 as December's top TV ad spender | ||
| 06.01. | 3 biopharma CEOs explain why they are 'authentically optimistic' for 2026 | ||
| 06.01. | AstraZeneca looks to grow reach in lupus with phase 3 win for self-administered Saphnelo | ||
| 05.01. | As Vyvgart empire expands, argenx CEO passes reins to operating chief Karen Massey | ||
| 05.01. | Bausch + Lomb brings glaucoma into focus with renewed awareness push | ||
| 05.01. | HCPs say pharmas' direct drug sale platforms have 'mixed' impact on GLP-1 access, care | ||
| 05.01. | Drugmakers raise prices of over 350 products, far outpacing last year: report | ||
| 05.01. | Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei | ||
| 05.01. | Novo's Wegovy pill makes US debut, with starter dose launching at $149 per month for cash-paying patients | ||
| 05.01. | Incyte to seek FDA approval for 7-drug Monjuvi regimen in 1st-line diffuse large B-cell lymphoma | ||
| 02.01. | Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA | ||
| 02.01. | Pacira brings Exparel DTC campaign to life with family-focused NYC event | ||
| 02.01. | Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win | ||
| 02.01. | After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder | ||
| 02.01. | Verastem nixes KRAS G12C plans in non-small cell lung cancer | ||
| 02.01. | Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.